Zoledronic acid seems to reduce risk of repeat breaks and death after hip fractureBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39343.363600.DB (Published 20 September 2007) Cite this as: BMJ 2007;335:584
- Janice Hopkins Tanne
- New York
Patients who had undergone surgical repair of hip fracture after a minor fall and who were then given an annual intravenous infusion of zoledronic acid were less likely to have a new vertebral fracture, to have a new non-vertebral fracture, or to die, a new study has found.
The international, double blind, placebo controlled study was released early by the New England Journal of Medicine (doi: 10.1056/NEJMoa074941). The trial was sponsored by Novartis, the manufacturer of the drug, which is marketed as Reclast in the United States and Aclasta in the United Kingdom.
Just over a third of patients aged over 50 who have had a hip fracture are likely to die within two years, write the authors of an accompanying editorial (doi: 10.1056/NEJMe078192), and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial